Institut du Cancer de Montpellier

Montpellier 34298

1 studies enrolling now · 8 studies all time

What they study most

Advanced Solid Tumors, Breast Cancer, Breast Neoplasms, Colorectal Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Glioblastoma, Leiomyosarcoma, Liposarcoma, Ovarian Cancer, Ovarian Neoplasms, Retroperitoneal Sarcoma, Solid Cancer, Squamous Cell Carcinoma of the Anal Canal, Squamous Non Small Cell Lung Cancer (NSCLC-SCC)

Studies at this site

• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer — Recruiting now
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — Recruiting now
• Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma — Recruiting now
• GEN1047 for Solid Tumors - First in Human (FIH) Trial — Stopped early
• Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). — Completed
• Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma — Completed
• Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma — Completed
• IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors — Stopped early